Earlier this week, I highlighted the disruptive genomics industry and recommended one way to gain diversified exposure to it: the ARK Genomic Revolution ETF (NYSE: ARKG).

Today, I’ll dive deeper into the field and offer you a way to gain access (for less than $4 a month) to one of my highest-conviction trades of the year: a “small DNA company” that’s already nearly doubled since I recommended it to my Green Zone Fortunes readers in late May.

And it’s just one of seven recommendations I’ve made in our portfolio that is beating the market 4.5-to-1 right now!

You see, DNA is literally the root of everything.

That makes it both fundamental to, and pervasive within, the fields of biotechnology and modern medicine.

My Experience With DNA Technology

I developed a respect for the importance of DNA nearly 20 years ago, when I worked on a research project with a Ph.D. geneticist between my junior and senior years of undergrad.

We ran toxicology studies using a DNA-sequencing process called polymerase chain reaction, or “PCR” for short.

Essentially, this process involved manufacturing a large number of copies of a single DNA sequence.

It’s almost laughable. The DNA technology we were using then was so primitive compared to what’s being done today, decades later.

As I shared with my Green Zone Fortunes readers in May, one small DNA company is now writing synthetic DNA sequences onto silicon chips, not unlike how semiconductor manufacturers write circuits onto silicon.

This company’s groundbreaking, proprietary technology allows it to pack roughly 10,000 times more DNA into the same space as traditional techniques. That gives it a massive advantage over its competitors.

And it offers the largest selection of high-quality synthetic DNA of anyone in the market today.

This company has shipped synthetic DNA to more than 1,000 customers around the world. And it’s averaged more than 140% annual increases in its customer base over the past four years!

There are three main reasons for this:

  • It has leveraged proprietary software.
  • It has an advanced robotics-driven manufacturing process.
  • Plus, the company is known for stellar customer service, including a seamless e-commerce ordering system.

Among its many customers, one is of particular interest in the “post-COVID” world.

COVID-19 and the DARPA “Sprint”

The company I’m recommending in my Green Zone Fortunes service was tapped in 2018 to provide custom synthetic DNA orders to researchers at the Vanderbilt Vaccine Center, as part of the Pandemic Prevention Platform program.

This program was funded primarily by the Defense Advanced Research Projects Agency (DARPA) — of the U.S. Department of Defense — and the National Institute of Allergy and Infectious Disease, of the National Institutes of Health.

This program was instrumental in developing a protective antibody-based treatment to the mosquito-transmitted Zika virus … in only 11 weeks!

Speaking on the so-called DARPA “sprint,” Associate Director Robert Carnahan, Ph.D., explained why the company I’m recommending is uniquely positioned to deliver:

[This company] is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage their biopharma capabilities, which we believe complement our antibody discovery efforts.

Now, as the entire world races to develop magic-bullet therapeutics and protective vaccines in the fight against COVID-19, you can bet your bottom dollar that this company is involved.

This Biotech Stock Is Still a “Buy”

It has already deployed the control sequences and research panels I discussed above.

It’s also continued to support Vanderbilt’s DARPA-funded Pandemic Prevention Platform. And it’s actively using its proprietary software and extensive database of DNA sequences to home in on dozens of potential antibodies that could prove effective at stopping the virus in its tracks.

Two days ago, I told my Green Zone Fortunes readers to lock in profits on a portion of their investment in the company, because, frankly, when you have the chance to lock in a near-100% profit in just four months … you take it!

The thing is, though … this stock is still a “buy.”

This little-known company was a “small-cap” stock when I recommended it. It was worth just $1.8 billion.

Today, it’s worth $3.6 billion.

But that’s still peanuts compared to the much larger size of established players in the biotech space. (These include Vertex Pharmaceuticals (VRTX), founded in 1989 and now worth $69 billion … Regeneron Pharmaceuticals (REGN), founded in 1988 and worth $59 billion … and Seattle Genetics (SGEN), founded in 1997 and worth $32 billion today.)

Your Access to This Top Genomics Stock

And I believe the company I’m recommending in my Green Zone Fortunes service has a unique and lucrative competitive advantage over even these established biotech companies.

My readers have already ridden the stock’s early rise, as it doubled in size and grew from a “small-cap” to a “mid-cap.”

But I think this company could double two more times ahead — from $3.6 billion to $7.2 billion, then to $14.4 billion — gaining admission to the $10 billion-plus “large-cap” category.

As I’ve said before, DNA is the future of everything in the health care sector. This company is in the driver’s seat of the genomic revolution with its proprietary “silicon chip” process and triple-digit revenue growth rates.

And you can gain access to my detailed recommendation on this biotech stock — plus a whole host of my other top stocks — by securing a subscription to my Green Zone Fortunes service today.

As I mentioned, this service is trouncing the market by 4.5-to-1. With a subscription cost of just $4 per month, buying one of my recommended stocks can pay for that in no time!

But you won’t just get the details on this biotech stock. You’ll also find out…

  • The digital payments provider I call “the frugal man’s PayPal.”
  • The Indian tech consulting company that Amazon picked as its premier tech partner.
  • My No. 1 play for the massive solar revolution.
  • The silver miner that will profit big-time when the metal soars in price.
  • The gold-mining stocks you must be in this year.
  • And every new recommendation I make … for the next year!

And I personally guarantee: You can try Green Zone Fortunes for 365 days. And if you don’t learn how to make the kind of money you want … or you don’t like my analysis … or you simply don’t like the font on the website … no worries!

You can cancel within the first year and receive a full refund of your subscription fee.

So, what do you have to lose? Get the details here.

To good profits,

Adam O’Dell, CMT